(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
2 days till quarter result
(bmo 2024-05-07)
Expected move: +/- 0.00%
0.00% ¥ 2 667.50
Live Chart Being Loaded With Signals
Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide...
Stats | |
---|---|
Volumen de hoy | 954 600 |
Volumen promedio | 1.32M |
Capitalización de mercado | 1 434.07B |
EPS | ¥0 ( 2024-02-06 ) |
Próxima fecha de ganancias | ( ¥28.50 ) 2024-05-07 |
Last Dividend | ¥27.00 ( 2023-06-29 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 24.75 |
ATR14 | ¥0.838 (0.03%) |
Volumen Correlación
Kyowa Kirin Co., Ltd. Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Kyowa Kirin Co., Ltd. Correlación - Moneda/Commodity
Kyowa Kirin Co., Ltd. Finanzas
Annual | 2023 |
Ingresos: | ¥442.23B |
Beneficio Bruto: | ¥320.62B (72.50 %) |
EPS: | ¥151.03 |
FY | 2023 |
Ingresos: | ¥442.23B |
Beneficio Bruto: | ¥320.62B (72.50 %) |
EPS: | ¥151.03 |
FY | 2022 |
Ingresos: | ¥398.37B |
Beneficio Bruto: | ¥311.46B (78.18 %) |
EPS: | ¥99.68 |
FY | 2021 |
Ingresos: | ¥352.25B |
Beneficio Bruto: | ¥264.40B (75.06 %) |
EPS: | ¥97.20 |
Financial Reports:
No articles found.
Kyowa Kirin Co., Ltd. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥0 (N/A) |
¥27.00 (N/A) |
¥0 (N/A) |
¥27.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥2.50 | 2000-03-28 |
Last Dividend | ¥27.00 | 2023-06-29 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 49 | -- |
Total Paid Out | ¥539.50 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.35 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.32 | |
Div. Directional Score | 9.55 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8369.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7762.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6937.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
6294.T | Ex Dividend Knight | 2024-03-28 | Annually | 0 | 0.00% | |
5018.T | Ex Dividend Knight | 2024-02-28 | Semi-Annually | 0 | 0.00% | |
4220.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3434.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
2540.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
9468.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
8097.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.184 | 1.500 | 6.33 | 9.49 | [0 - 0.5] |
returnOnAssetsTTM | 0.0791 | 1.200 | 7.36 | 8.83 | [0 - 0.3] |
returnOnEquityTTM | 0.101 | 1.500 | 9.99 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.358 | -1.000 | 6.42 | -6.42 | [0 - 1] |
currentRatioTTM | 4.59 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.93 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 3.03 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0232 | -1.500 | 9.61 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 535.43 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 214.94 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 153.83 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0285 | -1.500 | 9.89 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.742 | 1.000 | 0.962 | 0.962 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.230 | 1.000 | 7.40 | 7.40 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 4.84 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.431 | 0.800 | -0.460 | -0.368 | [0.5 - 2] |
Total Score | 12.77 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 17.66 | 1.000 | 8.32 | 0 | [1 - 100] |
returnOnEquityTTM | 0.101 | 2.50 | 9.99 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 153.83 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.10 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 214.94 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.358 | 1.500 | 6.42 | -6.42 | [0 - 1] |
pegRatioTTM | 0.432 | 1.500 | -0.450 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.261 | 1.000 | 5.97 | 0 | [0.1 - 0.5] |
Total Score | 6.32 |
Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico